

PATENT ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	SECURITY AGREEMENT
CONVEYING PARTY DATA	
Name	Execution Date
Concept Therapeutics Incorporated	08/16/2012
RECEIVING PARTY DATA	
Name:	Biopharma Secured Debt Fund II Sub, S.ar.l
Street Address:	65, Boulevard Grand-Duchesse Charlotte
City:	L-1331 Luxembourg
State/Country:	LUXEMBOURG
PROPERTY NUMBERS Total: 72	
Property Type	Number
Patent Number:	8097606
Patent Number:	7678813
Patent Number:	7928237
Patent Number:	7326697
Patent Number:	7402578
Patent Number:	6680310
Patent Number:	7163934
Patent Number:	7884091
Patent Number:	6369046
Patent Number:	7361646
Patent Number:	6150349
Patent Number:	6362173
Patent Number:	6964953
Patent Number:	6620802
Patent Number:	8173664
Patent Number:	7576076

CH \$2880.00 8097606

Application Number:	10896149
Application Number:	12238751
Application Number:	60489601
Application Number:	60489671
Application Number:	10772919
Application Number:	60445284
Application Number:	12691684
Application Number:	60535460
Application Number:	13345242
Application Number:	61430786
Application Number:	61492440
Application Number:	13046529
Application Number:	13398757
Application Number:	60551836
Application Number:	13476776
Application Number:	09942531
Application Number:	60229278
Application Number:	10087227
Application Number:	10949739
Application Number:	61651669
Application Number:	60750192
Application Number:	60869673
Application Number:	61013402
Application Number:	61122666
Application Number:	61287151
Application Number:	60167432
Application Number:	60376814
Application Number:	60316653
Application Number:	60307693
Application Number:	60424199
Application Number:	10137800
Application Number:	10533110
Application Number:	10703069
Application Number:	10533146
Application Number:	10628724

	10519008
Application Number:	60393660
Application Number:	60278523
Application Number:	60288619
Application Number:	60585018
Application Number:	61561644
Application Number:	12199114
Application Number:	60969027
Application Number:	61603491
Application Number:	13218809
Application Number:	61377558
Application Number:	13422399
Application Number:	61454289
Application Number:	12777340
Application Number:	61177483
Application Number:	60797265
Application Number:	13116239
Application Number:	61348553
Application Number:	12299265
Application Number:	13001211
Application Number:	61077248

CORRESPONDENCE DATA

Fax Number: 2028874288
Phone: 202-887-4000
Email: lgeyer@akingump.com
Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent via US Mail.
Correspondent Name: Laura Talley Geyer
Address Line 1: 1333 New Hampshire Ave, NW
Address Line 4: Washington, DISTRICT OF COLUMBIA 20036-1564

ATTORNEY DOCKET NUMBER: 687747.0012

NAME OF SUBMITTER: Laura Talley Geyer

Total Attachments: 20
source=Corcept - Patent Security Agreement#page1.tif
source=Corcept - Patent Security Agreement#page2.tif
source=Corcept - Patent Security Agreement#page3.tif

source=Corcept - Patent Security Agreement#page4.tif
source=Corcept - Patent Security Agreement#page5.tif
source=Corcept - Patent Security Agreement#page6.tif
source=Corcept - Patent Security Agreement#page7.tif
source=Corcept - Patent Security Agreement#page8.tif
source=Corcept - Patent Security Agreement#page9.tif
source=Corcept - Patent Security Agreement#page10.tif
source=Corcept - Patent Security Agreement#page11.tif
source=Corcept - Patent Security Agreement#page12.tif
source=Corcept - Patent Security Agreement#page13.tif
source=Corcept - Patent Security Agreement#page14.tif
source=Corcept - Patent Security Agreement#page15.tif
source=Corcept - Patent Security Agreement#page16.tif
source=Corcept - Patent Security Agreement#page17.tif
source=Corcept - Patent Security Agreement#page18.tif
source=Corcept - Patent Security Agreement#page19.tif
source=Corcept - Patent Security Agreement#page20.tif

PATENT SECURITY AGREEMENT

This Patent Security Agreement (the "Security Agreement") is made the 16th day of August, 2012, by and between **CORCEPT THERAPEUTICS INCORPORATED**, a Delaware corporation, and its permitted successors and assigns (the "Grantor") and **BIOPHARMA SECURED DEBT FUND II SUB, S.À.R.L.**, a private limited liability company (*société à responsabilité limitée*) organized under the laws of Luxembourg, and its permitted successors and assigns (the "Secured Party").

RECITALS

WHEREAS, reference is made to that certain Purchase and Sale Agreement ("the Agreement") dated as of the date hereof (and as amended, supplemented, restated, or otherwise modified from time to time), by and between the Grantor and the Secured Party;

WHEREAS, pursuant to the Agreement, the Grantor granted to the Secured Party a security interest in regards to all of Grantor's right, title, and interest in, to, and under the Additional Collateral, whether now owned or hereafter acquired by the Grantor and all of Grantor's rights and privileges with respect thereto;

WHEREAS the Grantor and the Secured Party have agreed to execute all documents to perfect the security interest of the Secured Party in such Additional Collateral of the Grantor, perfected and prior to all other Encumbrances thereon;

WHEREAS, in connection with the Agreement, the Grantor and the Secured Party have entered into this Security Agreement as of the date hereof (and as amended, supplemented, restated, or otherwise modified from time to time);

WHEREAS, the Grantor does hereby further acknowledge and affirm that the rights and remedies of the Secured Party with respect to the security interest in the Additional Collateral granted hereby are more fully set forth in the Agreement, the terms and provisions of which are incorporated by reference herein as if fully set forth herein.

WHEREAS, as a condition, among others, to the terms contemplated by the Agreement in regards to the Additional Collateral, the parties hereto execute this Security Agreement.

NOW THEREFORE, the parties hereto agree as follows:

1. Defined Terms. All capitalized terms used but not otherwise defined herein have the meanings ascribed to them, or incorporated by reference in, the Agreement.

2. Grant of Security Interest. Pursuant to the terms of the Agreement, Grantor hereby grants a security interest in all of its right, title, and interest in, to, and under all of the following Additional Collateral:

(a) all Product Patent Rights, which as of the Effective Date, consist of the Patents set forth on Exhibit A to this Security Agreement and all of Grantor's rights and privileges with respect thereto;

(b) all rights and privileges in registered and unregistered trademarks in the Territory which are owned or controlled by Grantor and related to Product, which as of the Effective Date, consist of the Product Trademarks set forth on Exhibit B to this Security Agreement, and all of Grantor's rights and privileges with respect thereto;

(c) all rights and privileges in the service marks, trade names, trade dress, logos, packaging design, slogans and Internet domain names which are owned or controlled by Grantor, and the registrations and applications for registration of any of the foregoing, in each case, as related to Product;

(d) all rights and privileges in the copyrights in both published and unpublished works which are owned or controlled by Grantor, including all compilations, databases and computer programs, manuals and other documentation and all copyright registrations and applications, and all derivatives, translations, adaptations and combinations of the above, in each case, as related to Product;

(e) all rights and privileges in Know-How which are owned or controlled by Grantor, in each case, as related to Product;

(f) all Regulatory Approvals;

(g) all Supporting Obligations (as such term is defined in the UCC) in respect of the foregoing and all collateral security and guarantees given by any Person with respect to any of the foregoing;

(h) all of Grantor's books and records relating to any and all of the foregoing; and

(i) all Proceeds (as such term is defined in the UCC) and products of and to any and all of the foregoing.

3. Reference to the Agreement. This Security Agreement has been entered into by the Grantor and the Secured Party solely for purposes as contemplated by the Agreement. In the event of any inconsistency between any of the terms or provisions hereof and the terms and provisions of the Agreement, the terms and provisions of this Security Agreement shall govern.

4. Termination. At the end of the Royalty Period, the Secured Party shall execute, acknowledge and deliver to the Grantor an instrument in writing in recordable form releasing the collateral pledge, grant, assignment, lien and security interest in the Product Patent Rights and Product Trademarks under this Security Agreement.

5. Counterparts. This Agreement may be executed in two or more counterparts, each of which will be an original, but all of which together will constitute one and the same instrument. To evidence the fact that it has executed this Agreement, a Party may send a copy of its executed counterpart to the other Parties by facsimile or other electronic transmission. In such event, such Party will forthwith deliver to the other Parties the counterpart of this Agreement executed by such Party.

6. Governing Law. This Security Agreement shall be construed in accordance with and governed by the laws of the State of New York, without giving effect to the principles of conflicts of law thereof.

[Signature page follows]

IN WITNESS WHEREOF, the Secured Party and the Grantor have caused this Agreement to be duly executed by their respective officers thereunto duly authorized, as of the day and year first set forth above.

BIOPHARMA SECURED DEBT FUND II SQR, S.A.R.L.
as the Secured Party

By: Pharmakon Advisors, LP, its investment
manager

By: Pharmakon Management I, LLC, its
general partner

By: 
Name: Pedro Gonzalez de Cosio
Title: Managing Member

CONCEPT THERAPEUTICS INCORPORATED
as the Grantor

By: _____
Name: _____
Title: _____

IN WITNESS WHEREOF, the Secured Party and the Grantor have caused this Agreement to be duly executed by their respective officers thereunto duly authorized, as of the day and year first set forth above.

BIOPHARMA SECURED DEBT FUND II SUB, S.À.R.L
as the Secured Party


By: Pharmakon Advisors, LP, its investment
manager

By: _____

Name: _____

Title: _____

CORCEPT THERAPEUTICS INCORPORATED
as the Grantor

By:  _____

Name: Charles Robb

Title: Chief Financial Officer

EXHIBIT A

PATENTS

TITLE	INVENTOR(S)	COUNTRY	PATENT NUMBER	APPLICATION NUMBER	PUBLICATION NUMBER	STATUS	FILING DATE
4-TRIFLUOROMETHYL-PHENYL SUBSTITUTED FUSED RING AZADECALIN MODULATORS		United States of America				Closed	
ALKYL-KETONE FUSED AZADECALIN MODULATORS		United States of America				Unfiled	
ANTI GLUCOCORTICOID THERAPY FOR THE PREVENTION OF NEUROLOGICAL DAMAGE IN PREMATURE INFANTS	Joseph Belanoff	United States of America		10896149	US-2005-0080061-A1	Closed	20-Jul-04
ANTI GLUCOCORTICOID THERAPY FOR THE PREVENTION OF NEUROLOGICAL DAMAGE IN PREMATURE INFANTS	Joseph Belanoff	United States of America		12238751	US-2009-0029959-A1	Closed	26-Sep-08
ANTI GLUCOCORTICOID THERAPY FOR THE PREVENTION OF NEUROLOGICAL DAMAGE IN PREMATURE INFANTS	Joseph Belanoff	United States of America		13034478	US-2011-0144072-A1	Closed	24-Feb-11
ANTI GLUCOCORTICOID THERAPY FOR THE PREVENTION OF NEUROLOGICAL DAMAGE IN	Joseph Belanoff	United States of America		60489601		Closed	23-Jul-03

PREMATURE INFANTS							
ANTIGLUCOCORTICIDS FOR THE TREATMENT OF CATATONIA	Joseph Belanoff	United States of America		60489671		Closed	23-Jul-03
ANTIGLUCOCORTICIDS FOR THE TREATMENT OF CATATONIA	Joseph K. Belanoff	United States of America	8097606	10896143	US-2005-0080066-A1	Issued	20-Jul-04
ANTIGLUCOCORTICIDS FOR THE TREATMENT OF POSTPARTUM PSYCHOSIS	Joseph Belanoff M.D.	United States of America		10772919	US-2004-0229855-A1	Closed	4-Feb-04
ANTIGLUCOCORTICIDS FOR THE TREATMENT OF POSTPARTUM PSYCHOSIS	Joseph Belanoff M.D.	United States of America		60445284		Closed	4-Feb-03
ANTIGLUCOCORTICIDS FOR THE TREATMENT POSTPARTUM DEPRESSION		United States of America				Closed	
AZADECALIN GLUCOCORTICOID RECEPTOR MODULATORS	Robin Douglas Clark, Nicholas Ray, Paul Blaney, Christopher Hurley, Hazel Hunt, David Clark, Karen Williams	United States of America		12691684	US-2010-0120759-A1	Published	21-Jan-10
AZADECALIN GLUCOCORTICOID RECEPTOR MODULATORS	Robin Douglas Clark, Nicholas Ray, Paul Blaney, Christopher Hurley, Hazel Hunt, David Clark, Karen Williams	United States of America	7678813	10596998	US-2007-0203179-A1	Issued	8-Mar-07
AZADECALIN GLUCOCORTICOID RECEPTOR MODULATORS	Robin Douglas Clark, Nicholas Ray, Paul Blaney, Christopher Hurley, Karen	United States of America		60535460		Closed	9-Jan-04

	Williams, Hazel Hunt, David Clark						
CHRONIC PAIN: GASTROESOPHAGEAL REFLUX DISEASE (GERD)	Joseph Belanoff M.D.	United States of America				Closed	
COMBINATION STEROID AND GLUCOCORTICOID RECEPTOR ANTAGONIST THERAPY	Joe Belanoff, Peter Lockey	United States of America		13345242		Pending	6-Jan-12
COMBINATION STEROID AND GLUCOCORTICOID RECEPTOR ANTAGONIST THERAPY	Joe Belanoff, Peter Lockey	United States of America		61430786		Pending	7-Jan-11
COMBINATION STEROID AND GLUCOCORTICOID RECEPTOR ANTAGONIST THERAPY	Joe Belanoff, Peter Lockey	United States of America		61492440		Pending	2-Jun-11
FUSED RING AZADECALIN GLUCOCORTICOID RECEPTOR MODULATORS	Robin D. Clark, Nicholas Ray, Paul Blaney, Christopher Hurley, Karen Williams	United States of America				Pending	16-Feb-12
FUSED RING AZADECALIN GLUCOCORTICOID RECEPTOR MODULATORS	Robin D. Clark, Nicholas Ray, Paul Blaney, Christopher Hurley, Karen Williams	United States of America		13046529	US-2011-0166110-A1	Closed	11-Mar-11
FUSED RING AZADECALIN GLUCOCORTICOID RECEPTOR MODULATORS	Robin D. Clark, Nicholas Ray, Paul Blaney, Christopher Hurley, Karen Williams	United States of America		13398757		Closed	16-Feb-12
FUSED RING AZADECALIN GLUCOCORTICOID RECEPTOR	Robin Douglas Clark, Nicholas Ray, Paul Blaney, Christopher Hurley	United States of America		60551836		Closed	9-Mar-04

MODULATORS							
FUSED RING AZADECALIN GLUCOCORTICOID RECEPTOR MODULATORS	Robin Douglas Clark, Nicholas Ray, Paul Blaney, Christopher Hurley, Karen Williams	United States of America		13476776		Pending	21-May-12
FUSED RING AZADECALIN GLUCOCORTICOID RECEPTOR MODULATORS	Robin Douglas Clark, Nicholas Ray, Paul Blaney, Christopher Hurley, Karen Williams	United States of America	7928237	10591884	US-2007-0281928-A1	Issued	7-May-07
GLUCOCORTICOID BLOCKING AGENTS FOR INCREASING BLOOD- BRAIN BARRIER PERMEABILITY	Alan Schatzberg	United States of America		9942531		Closed	29-Aug-01
GLUCOCORTICOID BLOCKING AGENTS FOR INCREASING BLOOD- BRAIN BARRIER PERMEABILITY	Alan Schatzberg	United States of America		60229278		Closed	30-Aug-00
GLUCOCORTICOID BLOCKING AGENTS FOR INCREASING BLOOD- BRAIN BARRIER PERMEABILITY	Alan Schatzberg, Steven Lindley, Joseph Belanoff M.D.	United States of America		10087227		Closed	27-Feb-02
GLUCOCORTICOID BLOCKING AGENTS FOR INCREASING BLOOD- BRAIN BARRIER PERMEABILITY	Alan Schatzberg, Steven Lindley, Joseph Belanoff M.D.	United States of America		10949739	US-2005-0124533-A1	Closed	24-Sep-04
GLUCOCORTICOID WITH STEROID PROPERTIES		United States of America				Unfiled	
HETEROARYL-KETONE FUSED AZADECALIN	Hazel Hunt, Tony Johnson, Nicholas Ray	United States of America		61651669		Pending	25-May-12

MODULATORS							
METHOD AND USE OF MIFEPRISTONE IN TREATMENT OF PARKINSON'S DISEASE		United States of America					Closed
METHOD FOR DOSING MIFEPRISTONE USING ALPHA-1 ACID GLYCOPROTEIN		United States of America					Closed
METHOD FOR REVERSING OR INHIBITING WEIGHT GAIN INDUCED BY ANTIDEPRESSANT MEDICATION	Joseph Belanoff	United States of America		60750192			Closed 13-Dec-05
METHOD FOR REVERSING OR INHIBITING WEIGHT GAIN INDUCED BY ANTIDEPRESSANT MEDICATION	Joseph Belanoff	United States of America		60869673			Closed 12-Dec-06
METHOD FOR REVERSING OR INHIBITING WEIGHT GAIN INDUCED BY ANTIDEPRESSANT MEDICATION	Joseph Belanoff	United States of America		61013402			Closed 13-Dec-07
METHOD FOR REVERSING OR INHIBITING WEIGHT GAIN INDUCED BY ANTIDEPRESSANT MEDICATION	Joseph Belanoff	United States of America		61122666			Closed 15-Dec-08
METHOD FOR REVERSING OR INHIBITING WEIGHT	Joseph Belanoff	United States of America		61287151			Closed 16-Dec-09

GAIN INDUCED BY ANTIDEPRESSANT MEDICATION							
METHOD FOR TREATING MILD COGNITIVE IMPAIRMENT USING A GLUCOCORTICOID-SPECIFIC RECEPTOR ANTAGONIST	Alan Schatzberg, Joseph Belanoff M.D.	United States of America		60167432		Closed	23-Nov-99
METHOD OF CONTROLLING HYPERGLYCEMIA IN PATIENTS USING AN ANTIGLUCOCORTICOID ANTAGONIST		United States of America				Closed	
METHOD OF TREATING THE PSYCHOSIS ASSOCIATED WITH PARKINSON'S DISEASE WITH A GLUCOCORTICOID RECEPTOR ANTAGONIST		United States of America				Closed	
METHODS AND COMPOSITIONS FOR TREATING INTERMITTENT EXPLOSIVE DISORDER ("IED")		United States of America				Closed	
METHODS FOR INCREASING THE THERAPEUTIC RESPONSE TO ELECTROCONVULSIVE THERAPY	Alan Schatzberg, Joseph Belanoff M.D.	United States of America		60376814		Closed	29-Apr-02

METHODS FOR INCREASING THE THERAPEUTIC RESPONSE TO ELECTROCONVULSIVE THERAPY	Alan Schatzberg, Joseph Belanoff M.D.	United States of America	7326697	10411503	US-2004-0029849-A1	Issued	8-Apr-03
METHODS FOR INHIBITING COGNITIVE DETERIORATION IN ADULTS WITH DOWN'S SYNDROME	Joseph Belanoff M.D.	United States of America	7402578	10230575	US-2003-0064974-A1	Issued	28-Aug-02
METHODS FOR INHIBITING COGNITIVE DETERIORATION IN ADULTS WITH DOWN'S SYNDROME	Joseph Belanoff M.D.	United States of America		60316653		Closed	31-Aug-01
METHODS FOR PREVENTING ANTIPSYCHOTIC-INDUCED WEIGHT GAIN	Joseph Belanoff M.D., Alan Schatzberg	United States of America		60307693		Closed	23-Jul-01
METHODS FOR PREVENTING ANTIPSYCHOTIC-INDUCED WEIGHT GAIN	Joseph Belanoff M.D., Alan Schatzberg	United States of America	6680310	10201356	US-2003-0027802-A1	Issued	22-Jul-02
METHODS FOR TREATING BONE LOSS USING GLUCOCORTICOID RECEPTOR-SPECIFIC ANTAGONISTS		United States of America				Closed	
METHODS FOR TREATING CHRONIC PAIN	Joseph Belanoff M.D.	United States of America				Closed	
METHODS FOR TREATING CHRONIC PAIN	Joseph Belanoff M.D.	United States of America		60424199		Closed	5-Nov-02

METHODS FOR TREATING DELIRIUM GLUCOCORTICOID RECEPTOR-SPECIFIC ANTAGONISTS	Joseph Belanoff M.D.	United States of America	7163934	10257656	US-2004-0029848-A1	Issued	12-May-03
METHODS FOR TREATING DELIRIUM USING GLUCOCORTICOID RECEPTOR-SPECIFIC ANTAGONISTS	Joseph Belanoff M.D.	United States of America		10137800		Closed	1-May-02
METHODS FOR TREATING DELIRIUM USING GLUCOCORTICOID RECEPTOR-SPECIFIC ANTAGONISTS	Joseph Belanoff M.D.	United States of America	7884091	11383017	US-2006-0194713-A1	Issued	12-May-06
METHODS FOR TREATING DEMENTIA		United States of America				Closed	
METHODS FOR TREATING DEMENTIA	Alan Schatzberg, Joseph Belanoff M.D.	United States of America	6369046	9246780		Issued	4-Feb-99
METHODS FOR TREATING GASTROESOPHAGEAL REFLUX DISEASE	Joseph Belanoff M.D.	United States of America		10533110		Closed	27-Apr-05
METHODS FOR TREATING GASTROESOPHAGEAL REFLUX DISEASE	Joseph Belanoff M.D.	United States of America	7361646	10702950	US-2004-0167110-A1	Issued	5-Nov-03
METHODS FOR TREATING MIGRAINE	Joseph Belanoff	United States of America		10703069	US-2004-0132703-A1	Published	5-Nov-03
METHODS FOR TREATING MIGRAINE	Joseph Belanoff M.D.	United States of America		10533146	US-2006-0052354-A1	Closed	27-Apr-05
METHODS FOR TREATING MILD COGNITIVE IMPAIRMENT USING A	Alan Schatzberg, Joseph Belanoff M.D.	United States of America		10628724	US-2004-0019028-A1	Closed	28-Jul-03

GLUCOCORTICOID-SPECIFIC RECEPTOR ANTAGONIST							
METHODS FOR TREATING PSYCHOSIS ASSOCIATED WITH GLUCOCORTICOID RELATED DYSFUNCTION	Alan Schatzberg, Joseph Belanoff M.D.	United States of America	6150349	9244457		Issued	4-Feb-99
METHODS FOR TREATING PSYCHOSIS ASSOCIATED WITH GLUCOCORTICOID RELATED DYSFUNCTION	Alan Schatzberg, Joseph Belanoff M.D.	United States of America	6362173	9639377		Issued	15-Aug-00
METHODS FOR TREATING PSYCHOSIS ASSOCIATED WITH INTERFERON-ALPHA THERAPY	Joseph Belanoff M.D.	United States of America		10519008	US-2006-0063748-A1	Published	21-Dec-04
METHODS FOR TREATING PSYCHOSIS ASSOCIATED WITH INTERFERON-ALPHA THERAPY	Joseph Belanoff M.D.	United States of America		60393660		Closed	2-Jul-02
METHODS FOR TREATING STRESS DISORDERS USING GLUCOCORTICOID RECEPTOR-SPECIFIC ANTAGONISTS	Joseph Belanoff M.D.	United States of America		60278523		Closed	23-Mar-01
METHODS FOR TREATING STRESS DISORDERS USING GLUCOCORTICOID RECEPTOR-SPECIFIC ANTAGONISTS	Joseph Belanoff M.D.	United States of America	6964953	10102448	US-2002-0169152-A1	Issued	19-Mar-02

METHODS OF TREATING DELIRIUM USING GLUCOCORTICOID RECEPTOR-SPECIFIC ANTAGONISTS	Joseph Belanoff M.D.	United States of America		60288619		Closed	4-May-01
METHODS OF TREATING MILD COGNITIVE IMPAIRMENT USING A GLUCOCORTICOID-SPECIFIC RECEPTOR ANTAGONIST	Alan Schatzberg, Joseph Belanoff M.D.	United States of America	6620802	9717703		Issued	20-Nov-00
MODIFIED PYRIMIDINE GLUCOCORTICOID RECEPTOR MODULATORS	Robin D. Clark, Nicolas Ray, Karen Williams, Peter Cracket, Gwen Hickin, David Clark	United States of America	8173664	12499753	US 2009-0275600 A1	Issued	8-Jul-09
MODIFIED PYRIMIDINE GLUCOCORTICOID RECEPTOR MODULATORS	Robin Douglas Clark, Nicholas Ray, Karen Williams, Peter Crackett, Gwen Hickin, David Clark	United States of America		60585018		Closed	2-Jul-04
MODIFIED PYRIMIDINE GLUCOCORTICOID RECEPTOR MODULATORS	Robin Douglas Clark, Nicholas Ray, Karen Williams, Peter Crackett, Gwen Hickin, David Clark	United States of America	7576076	11174096	US-2006-0025405-A1	Issued	29-Jun-05
OPTIMIZING MIFEPRISTONE ABSORPTION	Joe Belanoff, Robert Roe, Caroline Loewy	United States of America		61561644		Pending	18-Nov-11
OPTIMIZING MIFEPRISTONE LEVELS IN PLASMA SERUM OF PATIENTS SUFFERING FROM MENTAL DISORDERS TREATABLE WITH GLUCOCORTICOID	Joseph Belanoff	United States of America		12199114	US-2009-0062248-A1	Published	27-Aug-08

RECEPTOR ANTAGONISTS							
OPTIMIZING MIFEPRISTONE LEVELS IN PLASMA SERUM OF PATIENTS SUFFERING FROM MENTAL DISORDERS TREATABLE WITH GLUCOCORTICOID RECEPTOR ANTAGONISTS	Joseph Belanoff	United States of America		60969027		Closed	30-Aug-07
PHENYL HETEROCYCLOALKYL GLUCOCORTICOID RECEPTOR MODULATORS	Hazel Hunt, Tony Johnson, Nicholas Ray	United States of America		61603491		Pending	27-Feb-12
PYRIDYL-AMINE FUSED AZADECALIN MODULATORS	Robin Clark, Tony Johnson, Hazel Hunt, Ian McDonald	United States of America		13218809		Pending	26-Aug-11
PYRIDYL-AMINE FUSED AZADECALIN MODULATORS	Robin Clark, Tony Johnson, Hazel Hunt, Ian McDonald	United States of America		61377558		Closed	27-Aug-10
PYRIMIDINE CYCLOHEXYL GLUCOCORTICOID RECEPTOR MODULATORS	Robin Clark, George Hynd, Nicholas Ray, Mohammad Sajad	United States of America		13422399		Pending	16-Mar-12
PYRIMIDINE CYCLOHEXYL GLUCOCORTICOID RECEPTOR MODULATORS	Robin Clark, George Hynd, Nicholas Ray, Mohammad Sajad	United States of America		61454289		Pending	18-Mar-11
REDUCING SIDE EFFECTS OF		United States of America				Unfiled	

MIFEPRISTONE TREATMENT							
SOLID FORMS AND PROCESS FOR PREPARING	Robin Clark, Doug Fry	United States of America		12777340	US 2010-0292477 A1	Published	11-May-10
SOLID FORMS AND PROCESS FOR PREPARING	Robin Clark, Doug Fry	United States of America		61177483		Closed	12-May-09
THE USE OF A GLUCOCORTICOID RECEPTOR II ANTAGONIST TO TREAT DEPRESSION IN PATIENTS TAKING IL-2	Joseph Belanoff	United States of America		60797265		Closed	2-May-06
TREATING CHLAMYDIA USING GLUCOCORTICOID RECEPTOR ANTAGONISTS		United States of America				Closed	
TREATING INSOMNIA WITH ANTIGLUCOCORTICIDS		United States of America				Closed	
TREATING MILD COGNITIVE IMPAIRMENT IN DEPRESSED PATIENTS		United States of America				Closed	
TREATING VIRAL INFECTIONS USING GLUCOCORTICOID RECEPTOR ANTAGONISTS		United States of America				Closed	
TREATMENT OF MUSCULAR DYSTROPHY	Joseph Belanoff	United States of America		13116239	US-2011-0294771-A1	Published	26-May-11
TREATMENT OF MUSCULAR DYSTROPHY	Joseph Belanoff	United States of America		61348553		Closed	26-May-10
TREATMENT OF PRE-DIABETIC PATIENTS	Joseph Belanoff	United States of America				Closed	

TREATMENT OF THYROID CANCER WITH GLUCOCORTICOID RECEPTOR ANTAGONISTS		United States of America				Closed	
TREATMENT OF TRAUMATIC BRAIN INJURY WITH GLUCOCORTICOID RECEPTOR ANTAGONISTS		United States of America				Closed	
USE OF A GLUCOCORTICOID RECEPTOR II ANTAGONIST TO TREAT DEPRESSION IN PATIENTS TAKING IL-2	Joseph Belanoff	United States of America		12299265	US-2010-0179115-A1	Closed	2-May-07
USE OF ANTIPROGESTIN COMPOUNDS TO TREAT PREMENSTRUAL DYSPHORIA		United States of America				Closed	
USE OF MIFEPRISTONE FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS	Joseph Belanoff	United States of America		13001211	US-2011-0166115-A1	Published	30-Jun-09
USE OF MIFEPRISTONE FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS	Joseph Belanoff	United States of America		61077248		Closed	1-Jul-08
USE OF MIFEPRISTONE FOR TREATMENT OF PANCREATITIS		United States of America				Closed	

SV\915607.2

EXHIBIT B

TRADEMARKS

Country	Trademark	Application Number Application Date	Registration Number Registration Date	Class	Description of Services	Status	Next Renewal Date
United States	CORCEPT	78/092690 11/09/01	2924054 02/01/05	5	Pharmaceutical preparations for the treatment of psychiatric and neurological diseases and disorders in Class 05.	Registered	02/01/15
United States	KORLYM	85/218444 01/14/11		5	Pharmaceutical preparations for the treatment of psychiatric, neurological and endocrine diseases and disorders in Class 05.	Published	